Yuekun Qi
No. 99 West Huaihai Road
Xuzhou, 221002, China
Xuzhou, 221002, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.
Journal: BMC medicine
Published: February 07, 2026
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
Journal: Blood
Published: February 03, 2026
Effect of cytoreductive chemotherapy on the incidence of differentiation syndrome in patients with newly diagnosed acute promyelocytic leukemia.
Journal: Chinese medical journal
Published: July 26, 2025
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.
Journal: Frontiers in immunology
Published: January 24, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: November 30, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.
Journal: American journal of hematology
Published: May 16, 2024
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Journal: Cancer immunology, immunotherapy : CII
Published: January 12, 2024
Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
Journal: International immunopharmacology
Published: January 08, 2024
CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects.
CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects.
Journal: Cell reports. Medicine
Published: July 12, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 07, 2023
Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: August 30, 2022
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Journal: Cytotherapy
Published: August 18, 2022
Last Updated: 09/26/2026